Kazia Therapeutics (KZIA) announced that it has regained full compliance with all applicable listing standards of Nasdaq. On December 18, 2025, the company received written notification from Nasdaq confirming that Kazia has regained compliance with Nasdaq Listing Rule 5550(b)(1), the $2.5M minimum stockholders’ equity requirement, which serves as an alternative to the minimum market value of listed securities standard. Nasdaq further confirmed that the company is now in compliance with all applicable Nasdaq listing requirements, that the previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled as moot, and that Kazia’s American Depositary Shares will continue to trade on The Nasdaq Capital Market.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics files to sell 10.7M American depositary shares for holders
- Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance
- Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
- Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
- Kazia Therapeutics announces presentation from paxalisib studies